Viridian Therapeutics, Inc.\DE (VRDN)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $18.22
- As of
Kresmion compiles this page from VRDN's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Viridian Therapeutics, Inc.\DE (VRDN): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-06.
See the full VRDN dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for VRDN on one page. Preview it with sample data, then open it live with a free account.
Preview the VRDN dossierActive signals for VRDN
- highCONSENSUS_BUY
4 tracked funds increased VRDN this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +359% to VRDN (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1946% to VRDN (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +507% to VRDN (2026Q2)
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 96% of VRDN (2026Q2)
FREE, NO ACCOUNT
Every signal on VRDN, as it fires
You are seeing 5 of 11 signals recorded on VRDN since 2026-05-17.
The five above landed across 2 days. The other 6 were recorded on 2 other days. 8 of the 11 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in VRDN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 92790C104 · 2026Q2 | $43M | 0.05% | , |
| D. E. Shaw & Co., Inc.CUSIP 92790C104 · 2026Q2 | $21.7M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 92790C104 · 2026Q2 | $14.1M | 0.02% | , |
| CITADEL ADVISORS LLCCUSIP 92790C104 · 2026Q2 | $759K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, VRDN
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
VRDN against its peers
VRDN's operating margin of -512.9% ranks in the 41st percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | VRDN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 70.8M USD | 84.0M USD | 41 | 15 |
| Operating margin | -512.9% | -87.3% | 41 | 15 |
| Net margin | -483.6% | -195.7% | 44 | 16 |
| Return on equity | -47.4% | -36.3% | 45 | 20 |
| P / E | n/a | 7.9x | n/a | 5 |
| 1 year | -14.7% | 16.2% | 38 | 19 |
Peers (22): VERA, BCRX, MLYS, NVAX, VCEL, PHVS, AUPH, PVLA, VIR, LKFT, IMNM, NRIX, ADMA, CLDX, RXRX, SLS, SRPT, IRON, AGIO, MESO, ZYME, NTLA. Left out: ADRX (no annual filing), ZLDPF (no annual filing), GENB (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (VRDN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow VRDN on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to VRDN for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.